Probiotics for Depressive Symptomatology and Neural Activity. (PRODAN)
19 juin 2026 mis à jour par: Daniel Lamport, University of Reading
The Acute and Chronic Effects of Ecologic® Barrier on Depressive Symptoms and Neural Activation.
This study aims to investigate the acute and chronic effects of 16-week probiotic supplementation (Ecologic® Barrier) on depressive symptoms and neural activity in those with mild-to-moderate depression.
Aperçu de l'étude
Statut
Pas encore de recrutement
Intervention / Traitement
Description détaillée
This study will use a randomised, double-blind, placebo-controlled design. A total of 76 participants will be recruited and will receive either one sachet of the probiotic (Ecologic® Barrier) or one sachet of a placebo, matched in taste, smell, appearance, and packaging. Outcomes will be measured at baseline, 24 hours, and at 16 weeks for all participants. These include measures of general mood, depressive symptoms, executive function, and neural activity. Neural activation will be measured using electroencephalography (EEG), specifically measuring the P300 event-related potential (ERP) during an n-back task. In addition to the n-back task, executive function, specifically working memory and cognitive flexibility will be tested using the task-switching task.
The main question this study aims to answer is:
- Does probiotic supplementation result in improvements in the primary outcome measure of vulnerability and sensitivity to depression, as well as secondary measures of rumination, hopelessness/suicidality, acceptance/coping, aggression, control, and risk aversion?
- Does probiotic supplementation improve accuracy and response times in executive function and working memory, measured by the Task Switching Task (TST) and n-back task?
- Is probiotic supplementation associated with an increased P300 amplitude and shorter P300 latency compared to baseline measures during the n-back task, in parietal and frontal lobe regions, with more pronounced effects in the 2-back task?
- Is probiotic supplementation associated with changes in alpha and theta band activity and symmetry, particularly after completing a demanding working-memory task?
Type d'étude
Interventionnel
Inscription (Estimé)
76
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
London, Royaume-Uni, RG6 6UR
- School of Psychology and Clinical Languages
-
Contact:
- Vanessa Sofia Amaral Lopes Simoes
- Numéro de téléphone: 0118 987 5123
- E-mail: v.amarallopessimoes@pgr.reading.ac.uk
-
Sous-enquêteur:
- Vanessa Sofia Amaral Lopes Simoes
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Mild to moderate depression symptoms (BDI-II 12-28)
- Males and females
- Age range will be 25-40 years
- Right-handed participants only (required for EEG)
Exclusion Criteria:
- Taking antidepressants (up to 2 months prior to inclusion)
- Undergoing psychological treatment in the form of counselling, therapy or similar (up to 1 month prior to inclusion)
- Any diagnosed chronic medical condition (e.g. diabetes) or psychiatric illness.
- Use of antibiotics or laxatives (up to 3 months prior to inclusion)
- Use of probiotics and/or prebiotics (up to 1 month prior to inclusion)
- Enrolled in any other clinical trial (up to 1 month prior to inclusion)
- Following restrictive and/or unbalanced diets
- Smoking
- Continuous use of a weight-loss medication for more than one month prior to screening
- Significant gastrointestinal conditions affecting absorption, including but not limited to: inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end-stage renal disease; active cancer or cancer treatment within the past three years
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ecologic® Barrier
Participants will consume one sachet of Ecologic® Barrier powder(1x10^10 CFU/day), mixed in warm water with a meal.
The sachets can be stored at room temperature.
|
Ecologic® Barrier (1x1010 CFU/day).
Autres noms:
|
|
Comparateur placebo: Placebo powder
A placebo matched for packaging, visual appearance, smell, and taste will be given. Similar to the instructions on how to take the probiotic, subjects will consume one sachet per day, kept at room temperature, mixed into warm water with a meal. |
Matched placebo
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Leiden Index of Depression Sensitivity - Revised (LEIDS-R) vulnerability/sensitivity for depression.
Délai: Baseline and 16 weeks
|
A standardised measure of cognitive reactivity.
This questionnaire consists of 34 items, in which participants rate on a scale from 0 to 4, how strongly they feel each statement relates to them when they feel somewhat sad.
|
Baseline and 16 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Leiden Index of Depression Sensitivity - Revised (LEIDS-R). The following subscales are of interest: rumination, hopelessness/suicidality, acceptance/coping, aggression, control, and risk aversion.
Délai: Baseline, 24 hours, and 16 weeks
|
A standardised measure of cognitive reactivity.
This questionnaire consists of 34 items, in which participants rate on a scale from 0 to 4, how strongly they feel each statement relates to them when they feel somewhat sad.
|
Baseline, 24 hours, and 16 weeks
|
|
Beck Depression Inventory (BDI-II)
Délai: Screening, baseline, 24 hours, and 16 weeks
|
A robust tool consisting of 21 items used to measure the severity of depression.
It focuses on symptoms experienced in the last 2 weeks, such as cognitive and affective symptoms.
|
Screening, baseline, 24 hours, and 16 weeks
|
|
Mini-International Neuropsychiatric Interview (MINI)
Délai: Baseline, 24 hours, and 16 weeks
|
A short diagnostic interview designed to screen for 17 psychiatric disorders and the risk of suicide.
|
Baseline, 24 hours, and 16 weeks
|
|
Rumination Response Scale (RRS)
Délai: Baseline, 24 hours, and 16 weeks
|
A self-report questionnaire measuring the tendency to focus on negative thinking, distressing symptoms, and their causes when people feel down, sad, or depressed.
|
Baseline, 24 hours, and 16 weeks
|
|
Neural Activity
Délai: baseline, 24 hours, and 16 weeks
|
P300 event-related potential (ERP) amplitude and latency during the n-back task. Resting-state and active-state alpha and theta power oscillations. An exploratory measure of the N2 ERP may be analysed alongside the P300. |
baseline, 24 hours, and 16 weeks
|
|
Task-switching Task
Délai: Baseline, 24 hours, and 16 weeks
|
This is a measure of executive function and sustained attention.
Participants will be shown a circle with 8 equally spaced radii, 2 of which form a bold bisecting line.
Numbers are chosen randomly from a set of 1-4 & 6-9 and displayed sequentially in a clockwise direction.
A response of higher or lower than 5 is made for trials below the line, and a response of even or odd for numbers above the line.
Accuracy and reaction time (RT) on correct trials, as well as accuracy and RT on trials where there is a 'switch cost' from stimuli moving from below to above the bold line and vice versa, are the main outcome measures.
|
Baseline, 24 hours, and 16 weeks
|
|
N-back task
Délai: baseline, 24 hours, and 16 weeks
|
This is an executive function and working memory task.
There are varying difficulties of this task, but this trial will use the 0-back and 2-back versions.
The 0-back task involves participants being shown a sequence of letters and having to respond when the current letter matches that of the previous letter.
In the 2-back task, participants will have to respond when the current letter matches the letter from two trials ago.
|
baseline, 24 hours, and 16 weeks
|
|
Profile of Mood States short form (POMS-SF)
Délai: Baseline, 24 hours, and 16 weeks
|
This is a condensed self-report questionnaire used to measure changes in mood, assessed across 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigour-activity, fatigue-inertia, and confusion-bewilderment) with 40 total items.
A total mood disturbance score is provided.
|
Baseline, 24 hours, and 16 weeks
|
|
Visual Analogue Scale (VAS) of Positive and Negative feelings
Délai: Every day from baseline to the final 16-week time point.
|
Visual Analogue Scale of positive/negative feelings via a daily assessment.
This includes two questions asking participants to rate on a scale from 0 to 100 the extent to which they felt positive or negative feelings.
|
Every day from baseline to the final 16-week time point.
|
|
Quality of Life (SF12)
Délai: Baseline, 24 hours, and 16 weeks
|
The Quality of Life (SF12) is a questionnaire which asks for participants' views about their health.
This information keeps track of how they feel and how well they can do their usual activities.
|
Baseline, 24 hours, and 16 weeks
|
|
Gastrointestinal Symptom Rating Scale (GSRS)
Délai: Baseline, 24 hours, and 16 weeks
|
This is a 15-item self-reported questionnaire assessing the severity of gastrointestinal symptoms.
It uses a 7-point Likert scale, covering five symptom domains: reflux, abdominal pain, indigestion, diarrhoea, and constipation symptoms.
|
Baseline, 24 hours, and 16 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Generalised Anxiety Disorder-7 (GAD-7)
Délai: Baseline
|
This is a self-report questionnaire used to measure the severity of generalised anxiety disorder.
It has seven items and asks individuals to rate the frequency of anxiety symptoms over the past two weeks, with scores ranging from 0 to 21 to determine anxiety levels.
Baseline scores may be used as a covariate.
|
Baseline
|
|
Menstrual Cycle Data
Délai: Baseline and 16 weeks
|
Information regarding the first day of the most recent menstruation, regularity and contraception will be recorded.
It is not a direct outcome measure, but data may be used as a covariate.
|
Baseline and 16 weeks
|
|
Epic-Norfolk Food Frequency Questionnaire (FFQ)
Délai: Baseline and 16 weeks
|
This is a validated tool for analysing the average habitual dietary intake of micro and macronutrients of an individual in the UK, which is particularly important to explore in order to understand how the probiotic supplement may interact with diet and gut microbiome diversity.
Data will be processed using the FETA software.
|
Baseline and 16 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 juillet 2026
Achèvement primaire (Estimé)
1 mars 2027
Achèvement de l'étude (Estimé)
1 mars 2027
Dates d'inscription aux études
Première soumission
19 juin 2026
Première soumission répondant aux critères de contrôle qualité
19 juin 2026
Première publication (Réel)
25 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
25 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
19 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UReading Probiotics Depression
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .